-
A Preview Of January PDUFA Dates
Wednesday, December 28, 2016 - 12:10pm | 691Read More...Biopharma companies did not have much to write home about in the year 2016, as negative news flow on price gouging hit many stocks in the space. The SPDR S&P Biotech (ETF) (NYSE: XBI) and the iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB) are down 13.93 percent and 20.36 percent,...
-
Anacor Shares Surge To All-Time Highs After Phase 3 Trials Of Eczema Drug
Monday, July 13, 2015 - 3:29pm | 529Read More...In a public conference call on Monday, Anacor Pharmaceuticals Inc (NASDAQ: ANAC) executives announced the results of two Phase 3 trials for a topical drug to treat atopic dermatitis, more commonly known as eczema. The treatment came in the form of a topical ointment, crisaborole. Atopic dermatitis...
-
Wedbush On Anacor Pharma: Crisaborole Delivers, Reiterate Outperform
Monday, July 13, 2015 - 2:33pm | 254Read More...In a report rolled out Monday, Wedbush analysts David M. Nierengarten, Dilip Joseph and Robert Driscoll reiterated an Outperform rating on shares of Anacor Pharmaceuticals Inc (NASDAQ: ANAC), while boosting their price target from $85 to $190. Shares of Anacor were up more than 55 percent on...
